1751 River Run
Suite 400
Fort Worth, TX 76107
United States
817 438 6168
https://tffpharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 19
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Harlan F. Weisman | President, CEO & Director | 742.5k | N/A | 1952 |
Mr. Kirk Allen Coleman | CFO, Treasurer & Secretary | 409.94k | N/A | 1974 |
Dr. Zamaneh Mikhak M.D. | Chief Medical Officer | 545.38k | N/A | 1964 |
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.
TFF Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.